CitiusTech Senior VP and Market Head, Healthcare Providers, John Squeo, shares five game-changing shifts that will redefine the future of US healthcare and unlock a more streamlined, accessible and patient-centric system.
Medical Device Original Equipment Manufacturers (OEMs) are increasingly seeking sophisticated thermal solutions to improve medical device performance. How does the transition from traditional heaters to advanced, layered heater technologies impacts device design?
North Carolina healthcare provider supplies clinicians with immediate, on-site access to 3D-printed anatomic models and support through Ricoh Managed Services.
Typically, costs are reduced by using less material and floor space, and eliminating any specialty equipment required for handling large or heavy parts. For miniature devices, the equation is reversed.
The new equity guide provides implementation steps to help developers and users implement the AHRQ Digital Healthcare Equity Framework to ensure new technologies ameliorate, rather than exacerbate, inequities in health care.
The push to use smaller packages can be counterproductive. The better solution may be to reduce the size of external components or eliminate them entirely and integrate their functionality into highly integrated ICs.
“In the future, CDRH intends to increase the breadth of the dataset of chemicals and RRF information it makes publicly available, and to add other detection methodologies such as liquid chromatography (LC).”
“Companies that operate with business integrity elevate industry standards and perform better in the long-term. We are impressed with Flex’s continued focus on ethical business practices, and dedication to making a real impact for its stakeholders.”
Product developers need to understand the technical challenges in device miniaturization but should be careful not to go beyond what is needed for the product. Sometimes further miniaturization is critical to the success of a product, sometimes it is superfluous, and sometimes it is even detrimental.
While pharmacogenomics has traditionally been the domain of academic research, policymakers are now showing a burgeoning interest in its potential to enhance patient outcomes and mounting evidence from the pharmaceutical industry is fueling interest in this field.